NextCure (NASDAQ:NXTC) Stock: Insider Adar1 Capital Management, Llc Buys 3,662 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 3,662 shares of the company’s stock in a transaction on Friday, November 6th. The stock was acquired at an average price of $5.10 per share, with a total value of $18,676.20. Following the completion of the purchase, the insider directly owned 737,956 shares in the company, valued at $3,763,575.60. This trade represents a 0.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, November 5th, Adar1 Capital Management, Llc acquired 1,024 shares of NextCure stock. The shares were purchased at an average price of $5.10 per share, with a total value of $5,222.40.
• On Tuesday, October 27th, Adar1 Capital Management, Llc bought 3,553 shares of NextCure stock. The stock was purchased at an average cost of $5.10 per share, for a total transaction of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc bought 1,672 shares of NextCure stock. The stock was purchased at an average price of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock. The stock was purchased at an average price of $4.83 per share, for a total transaction of $27,173.58.

NextCure Stock Up 17.6%

NextCure stock traded up $0.94 during midday trading on Monday, reaching $6.27. 58,474 shares of the stock traded hands, compared to its average volume of 676,034. The stock’s fifty day moving average is $6.06 and its 200-day moving average is $7.70. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74. The stock has a market cap of $22.65 million, a P/E ratio of -0.72 and a beta of 1.22.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Institutional Investors Weigh In On NextCure

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC increased its holdings in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,534 shares of the company’s stock after buying an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.65% of the company’s stock.

Wall Street Analyst Weigh In

NXTC has been the subject of several analyst reports. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 26th. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.